Abstract:Introduction: Genomic scale copy number, methylation, and fragmentation aberrations are proven genetic and epigenetic biomarkers of circulating tumor DNA (ctDNA). We developed a novel cell-free DNA (cfDNA) methylome sequencing assay that allows for integrative analysis of these genomic features for sensitive detection of multiple types of cancer. Methods: Whole methylome sequencing (WMS) libraries were generated from enzymatically converted cfDNA. Low-pass (~2X) paired-end NGS sequencing was performed on WMS libraries and paired whole genome sequencing (WGS) libraries of unconverted cfDNA for technical comparison and analytical validation. For development of cancer detection models, we profiled the genome-wide methylation density (MD), fragment size index (FSI), fragment end motif (motif) and chromosome instability (CIN) based on WMS data from a discovery cohort of 352 healthy controls and 559 newly diagnosed cancer patients (45 breast, 105 colorectal, 44 esophageal, 79 gastric, 79 liver, 110 lung, 83 pancreatic, and 14 others), 34.5% of which were at stage I or II. Machine learning models, including KNN, SVM, LR, GBDT, and random forest were trained and tested for individual biomarker types, with a final ensemble classifier to integrate all biomarkers. Performance of the predictive model was confirmed on an independent validation cohort consisting of 145 healthy controls and 236 cancer patients (21 breast, 45 colorectal, 18 esophageal, 35 gastric, 34 liver, 47 lung, and 36 pancreatic), among which 31.8% were at early stages (I or II). Results: WMS and WGS data from 512 cfDNA samples showed high concordance in CIN (R=0.988, 95% CI: 0.986-0.990) and FSI (R=0.961, 0.954-0.967) profiles. On the independent validation cohort, the optimal model selected for each of individual genomic features achieved following area under the ROC curve (AUC) values for cancer detection: MD-KNN, 0.830 (0.789-0.870); FSI-SVM, 0.904 (0.874-0.933); motif-SVM, 0.943 (0.920-0.966); and CIN-PAscore, 0.812 (0.770-0.854). The ensemble classifier based on linear SVM outperformed individual biomarkers, with an AUC value of 0.952 (0.934-0.971), which translated to, at 95% specificity, detection sensitivity of 66.7% for breast, 77.8% for colorectal, 83.3% for esophageal, 62.9% for gastric, 82.4% for liver, 66.0% for lung, and 77.8% for pancreatic cancers. Noteworthily, the overall sensitivity on early-stage cancer was 74.7%. Conclusions: These results demonstrate the first proof of principle on the feasibility of integrating multiple genomic cancer markers on the same WMS technical platform. Low-pass WMS on plasma cfDNA from 10ml of blood with integrative multimodal analysis of methylation, fragmentation, and CNV profiles yields in satisfactory sensitivity and specificity for detection of multiple types of cancer, warranting a forthcoming prospective study to further assess its clinical performance in a larger cohort. Citation Format: Yulong Li, Fenglong Bie, Fengwei Tan, Tiancheng Han, Shunli Yang, Fang Lv, Peiyao Nie, Qi Zhang, Yuanyuan Hong, Zhijie Wang, Ji He, Weizhi Chen, Liang Zhao, Shugeng Gao. Multimodal analysis of plasma cell-free DNA methylome for sensitive multi-cancer detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5150.

Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning

Whole-genome bisulfite sequencing analysis of circulating tumour DNA for the detection and molecular classification of cancer

Sensitive tumour detection and classification using plasma cell-free DNA methylomes

CancerScreen: A Novel Ultrasensitive Liquid Biopsy for Early-Stage Cancer Detection by Ctdna Duplex Sequencing and Tissue of Origin Identification with Supervised Machine Learning.

Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA

Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification

Early Non-Invasive Detection Of Stage La Lung Cancer Using Circulating Tumor Dna Methylation Haplotypes (Ctmdna) In Plasma.

Ultrasensitive DNA Hypermethylation Detection Using Plasma for Early Detection of NSCLC: a Study in Chinese Patients with Very Small Nodules.

Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer

An Ultrasensitive Method for Noninvasive Pan-Cancer Early Detection Based on Targeted Methylation Sequencing of Cell-Free DNA.

Early detection and stratification of lung cancer aided by a cost-effective assay targeting circulating tumor DNA (ctDNA) methylation

Non-invasive Diagnosis of Nature of Pulmonary Nodules Using the Whole Genome Methylation Sequencing of Circulating Cell-Free DNA.

Circulating tumor DNA methylation marker-based minimal residual diseases detection and recurrence monitoring of cancer.

Noninvasive Lung Cancer Early Detection via Deep Methylation Representation Learning.

Abstract 3249: Detection of Early-Stage Malignant Lung Cancer Using Methylation Signatures in Circulating Tumor DNA

The Early Diagnosis in Lung Cancer by the Detection of Circulating Tumor DNA

An ultrasensitive approach for cancer screening and tissue of origin prediction based on targeted methylation sequencing of cell-free DNA.

Abstract 5150: Multimodal analysis of plasma cell-free DNA methylome for sensitive multi-cancer detection

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Development of a cfDNA based trans-omics approach for early cancer detection

A novel artificial intelligence-enhanced electrochemical method for rapid methylation detection in cfDNA: Advancing multi-cancer early diagnosis.